Efficacy of Rituximab Biosimilar in Follicular Lymphoma
A phase III study looks at the efficacy and safety of rituximab biosimilar CT-P10 in patients with follicular lymphoma.
Lynch Syndrome More Prevalent Than Previously Thought
Microsatellite instability and or mismatch repair deficiency found predictive of LS across a broader tumor spectrum than previously thought.
Treatment-Related Cardiotoxicity in Pediatric AML
A study looks at the occurrence of treatment-related cardiotoxicity and its impact on pediatric AML patients.
Race and Efficacy of Monoclonal Antibodies in Multiple Myeloma
Does patient race play a role in the efficacy of monoclonal antibodies in multiple myeloma?
Impact of Elotuzumab on Multiple Myeloma Patients
The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma.
Do Cash Incentives Improve CRC Screening Rates?
A study takes a closer look at colorectal cancer screening incentives among New York State Medicaid managed care patients.
The Link Between Diet Quality and CRC Outcomes
A study looks at how dietary patterns impact colorectal cancer outcomes before and after diagnosis.
'Game-changing' New Treatment for NHS Lymphoma Patients
Cancer patients in England will receive a new game-changing therapy treatment under the first negotiated deal of its kind struck in Europe.
New Guidelines for Early-Stage Melanoma Treatment
The American Academy of Dermatology published new clinical practice guidelines with recommendations for the treatment of primary cutaneous melanoma.
Inflammation Marker Prognostic in DLBCL
An inflammation marker was associated with several unfavorable characteristics in diffuse large B-cell lymphoma.
Variation in Quality of Post-Surgery Cancer Care
A study of more than 350 hospitals found variations in readmission and mortality rates after cancer surgical procedures.
Reduced-Dose Ibrutinib Remains Effective in CLL
A study shows that lower doses of ibrutinib after a full-dose cycle may be enough for continued biological activity.
Ibrutinib/BR Combo Improves Survival in CLL
Long-term data from the phase III HELIOS trial indicates ibrutinib plus bendamustine and rituximab improve survival outcomes in CLL patients.
Should RCC Patients With Nodal Disease be Reclassified?
A study shows stage III renal cell carcinoma patients with nodal disease may need to be reclassified.
Checkpoint Inhibitors Highly Active in Metastatic RCC
A study shows RCC patients overall response rate did not decline from the first‐line to the fourth‐line of IO therapy.
PET-CT Responses After First-Line Immunochemotherapy in FL
Evaluating the prognostic value of PET-CT responses after first-line immunochemotherapy in follicular lymphoma.
FDA Approves Once-Weekly Carfilzomib for Myeloma
FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.
Thalidomide-Based Treatment Too Risky in Multiple Myeloma?
A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.
Improving Colorectal Cancer Screening For the Underserved
A study of an equal-access military health system shows universal health insurance for both the military and civilian populations could improve CRC screening rates.
ZEB2 Biomarker May Improve TNM Risk-Stratification in CRC
A study shows ZEB2 has clinical potential and may improve TNM risk-stratification and guide treatment in colorectal cancer.
MRD Status May Outweigh Cytogenetic Risk as Prognostic Marker for Myeloma
Minimal residual disease negativity measured by next-generation sequencing was a valuable prognostic biomarker for multiple myeloma.
Experienced Providers Linked With Improved OS in DLBCL
A study shows undergoing treatment for DLBCL at a clinic with more experience was linked with important clinical outcomes.
Pediatric Melanoma More Common in Melanoma-Prone Families
The percentage of patients with pediatric melanoma is 6-fold to the 28-fold higher when compared with the general population of patients with melanoma.
Stress Linked with Biomarkers of Poor Prognosis in CLL
A study shows stress may affect certain cellular, cytokine, and chemokine markers in the body of patients with CLL.
Ibrutinib Superior to Chemoimmunotherapy in Treatment-Naive CLL
A study shows treatment with ibrutinib is superior to chemoimmunotherapy for patients with chronic treatment-naive CLL.
Differentiating Benign Renal Tumors From Chromophobe RCC
A radiographic measure may help clinicians distinguish between benign renal oncocytoma and chromophobe renal cell carcinoma.
Partial Nephrectomy Linked to Improved OS in T1a RCC
A study shows T1a RCC patients have improved overall survival when receiving partial nephrectomy compared with radical nephrectomy.
Pazopanib Active in von Hippel-Lindau Disease
Patients with von Hippel-Lindau disease may have a new treatment option in the antiangiogenic therapy pazopanib.
Hyperprogression in NSCLC Patients With PD-1/PD-L1 Inhibitors
A study shows hyperprogressive disease (HPD) occurred more commonly among patients with pretreated non-small cell lung cancer (NSCLC) receiving PD-1/PD-L1 inhibitors.
Insurance Status Linked with Follicular Lymphoma Outcomes
A study shows expanding access to care through insurance has the potential to improve outcomes in adults with follicular lymphoma.